Q2 2026 Drug Updates: New FDA Approvals, Generics and Biosimilars to Watch
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh In Q2 2026, the FDA approved several […]
Your PBM Contract Has Fine Print. The Fine Print Is Where the Money Is.
By Giorgio Vescera, Vice President of Underwriting and Analytics at Navion Most PBM contracts are won on the pricing grid. That
What Plan Sponsors Need to Know About HIV Treatment, PrEP and Pharmacy Costs
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh HIV prevention and treatment options are expanding
Everyone’s Talking About Pharmacogenomics. The Hard Part Is Making It Work
By Jason Peterson, RPh, Director of Clinical Strategy at Navion For decades, prescribing medication has followed a frustratingly familiar rhythm: try a
GLP-1 Market Update: Oral Drugs, New Formulations, Pipeline Activity, and Pricing Shifts
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh New products are only part of what’s changing in the GLP-1 market. The
International Drug Sourcing Is Under Scrutiny. What Employers Should Understand Before Adopting It
By Jason Peterson, RPh, Director, Clinical Strategy & Monica Gindhart, Vice President Of Business Development For years, international sourcing—where medications are obtained
Direct-to-Consumer (DTC) Prescription Drug Programs
A Simple FAQ for Employers Several drug manufacturers now offer certain medications directly to patients at published cash prices. These
